Sophia Genetics reports Q4 EPS (37c) vs. (22c) last year

Reports Q4 revenue $17.0M, consensus $17.33M. “We are pleased with the tremendous performance in fiscal year 2023, including 31% year-over-year revenue growth, continued gross margin expansion, and 36% year-over-year improvement in cash burn,” said CEO Jurgi Camblong. “During 2023, we were excited to see continued, widespread adoption of SOPHiA DDM worldwide as the Platform performed a record 317,000+ analyses across the 450 core genomics customers we serve. We are especially proud of the growth we delivered with SOPHiA DDM’s Solid Tumor applications, with our BioPharma partners, and in the U.S. market.” Camblong added, “Looking forward to 2024, we are well positioned to continue delivering strong growth. SOPHiA DDM’s new Liquid Biopsy offering, world-class Solid Tumor applications, and the momentum we are building in the U.S. are all exciting catalysts for growth in 2024 as we continue on our path to profitability in the next 2+ years.”